Discovery Laboratories has begun the U.S. commercial launch of Surfaxin (lucinactant) Intratracheal Suspension for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first FDA-approved synthetic, peptide-containing surfactant and the only alternative to animal-derived surfactants available in the U.S., according to a company statement.

Most common adverse reactions associated with the use of Surfaxin are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During Surfaxin administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant’s clinical condition assessed and stabilized. Surfaxin is not indicated for use in acute respiratory distress syndrome (ARDS).